Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.16Last Year’s EPS
0.31Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution and financial performance in 2025 — including 19% total revenue growth to $3.7B, substantial proprietary product momentum (EPKINLY +67% to $468M; TIVDAK +26% to $164M), operating profit expansion to $1.26B, and strategic pipeline enhancement via the Merus acquisition (petosemtamab). Management outlined multiple near‑term clinical catalysts (up to six potential registrational readouts in 2026) and a disciplined capital allocation plan, while also acknowledging important challenges: a Phase III EPKINLY monotherapy study where OS missed statistical significance (confounded by COVID and evolving treatment landscape), higher operating expenses to fund launches and development (+13%), and increased leverage and financing costs following the acquisition. Overall, the positives — durable revenue and product growth, a deeper late‑stage pipeline with compelling early data, and clear guidance on investments and deleveraging — materially outweigh the clinical and financing risks discussed, although these risks warrant monitoring as the 2026 readouts and regulatory interactions unfold.Company Guidance
Strong Revenue Growth
Total revenue increased 19% year-over-year to $3.7 billion in FY2025, reflecting growth across royalty streams and commercialized medicines.
Rapid Growth of Proprietary Medicines
Sales of Genmab's proprietary medicines totaled $632 million, up 54% year-over-year and accounting for ~28% of total revenue growth.
EPKINLY Commercial Momentum
EPKINLY generated $468 million in sales in 2025, a 67% year-over-year increase; approved in more than 65 countries and positioned as a dual-indication bispecific across DLBCL and follicular lymphoma.
TIVDAK Market Traction
TIVDAK sales reached $164 million in 2025, up 26% year-over-year, with approvals in the EU, U.K., Japan and continued U.S. growth as a standard of care in recurrent/metastatic cervical cancer.
Improved Profitability
Operating profit expanded to $1.26 billion in 2025 despite strategic investments, demonstrating operating leverage as the business scales.
Bolt-on Acquisition Strengthening Late‑Stage Pipeline
Merus acquisition added petosemtamab to Genmab's late-stage portfolio, expanding high-impact assets alongside EPKINLY and Rina-S and increasing potential future launch catalysts.
Compelling Early Clinical Data for Petosemtamab
In first-line head and neck cancer, petosemtamab plus pembrolizumab achieved a 63% response rate, versus ~19% with standard of care—supporting multibillion-dollar potential.
Robust Late‑Stage Pipeline and Regulatory Recognition
Three late-stage programs (EPKINLY, Rina-S, petosemtamab) hold five combined breakthrough therapy designations; company expects up to six potentially registrational data readouts in 2026 that could enable 2027 launches.
Guidance and Capital Allocation Discipline
2026 midpoint guidance anticipates ~14% revenue growth and $1.15 billion operating profit at midpoint while reaffirming capital allocation priorities, pipeline investment, and a target to reduce gross leverage below 3x by end of 2027.
Debt Financing Completed
Completed a $5.5 billion debt offering ($2.5B fixed, $3.0B floating) with ~$1.6B of the floating portion hedged to fixed (net ~$4.1B fixed) to support the Merus acquisition and integration.
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $30.03 | $30.00 | -0.10% |
Nov 10, 2025 | $28.66 | $29.06 | +1.40% |
Aug 07, 2025 | $21.51 | $22.69 | +5.49% |
May 08, 2025 | $20.60 | $19.42 | -5.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Genmab A/S (GMAB) report earnings?
Genmab A/S (GMAB) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Genmab A/S (GMAB) earnings time?
Genmab A/S (GMAB) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2026 (Q1) is 0.16.